



1632

24024

PATENT TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number 10/052,589

Filing Date January 18, 2002

First Named Inventor Dianne M. Perez

Group Art Unit 1632

Examiner Name Not yet assigned

Attorney Docket Number 26473/04200

Total Number of Pages in This Submission

**RECEIVED**

APR 23 2002

TECH CENTER 1600/2900

**ENCLOSURES (check all that apply)**

- ☐ Fee Transmittal Form  
☐ Fee Attached  
☐ Amendment / Reply  
☐ After Final  
☐ Affidavits/declaration(s)  
☐ Extension of Time Request  
☐ Express Abandonment Request  
☒ Information Disclosure Statement  
☐ Certified Copy of Priority Document(s)  
☐ Response to Missing Parts/ Incomplete Application  
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)  
☐ Drawing(s)  
☐ Licensing-related Papers  
☐ Petition  
☐ Petition to Convert to a Provisional Application  
☐ Power of Attorney, Revocation Change of Correspondence Address  
☐ Terminal Disclaimer  
☐ Request for Refund  
☐ CD, Number of CD(s) \_\_\_\_\_

- ☐ After Allowance Communication to Group  
☐ Appeal Communication to Board of Appeals and Interferences  
☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  
☐ Proprietary Information  
☐ Status Letter  
☒ Other Enclosure(s) (please identify below):

Return Receipt  
Postcard

Remarks

**RECEIVED**

APR 23 2002

TECH CENTER 1600/2900

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**Firm  
or  
Individual name

Pamela A. Docherty, Reg. No. 40,591

Signature

Pamela A. Docherty

Date

April 15, 2002

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: APRIL 15, 2002

Typed or printed name

Wendy A. Frick

Signature

Wendy A. Frick

Date

April 15, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



APR 19 2002

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Comple if Kn wn

Application Number	10/052,589
Filing Date	January 18, 2002
First Named Inventor	Dianne M. Perez
Group Art Unit	1632
Examiner Name	Not yet assigned
Attorney Docket Number	26473/04200

TECH CENTER 1500/2800

APR 23 2002

RECEIVED

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4.	PEREZ, ET AL., "Constitutive Activation of a Single Effector Pathway: Evidence for Multiple Activation States of a G Protein-Coupled Receptor" Molecular Pharmacology, 49:112-122 (1996).	
	5.	ZUSCIK, ET AL., "Cloning, Cell-Type Specificity, and Regulatory Function of the Mouse •1B-Adrenergic Receptor Promoter" Molecular Pharmacology, 56:1288-1297 (1999).	
	6.	SALLINEN, ET AL., "Genetic Alteration of •2C-Adrenoceptor Expression in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects of Dexmedetomidine, a Subtype-Nonselective •2-Adrenoceptor Agonist" Molecular Pharmacology, 51:36-46 (1997).	
	7.	HWA, ET AL., "Synergism of Constitutive Activity in •1-Adrenergic Receptor Activation" Biochemistry, Vol. 36, No. 3, pp. 633-639, 1997.	
	8.	HOCHER, ET AL., "Endothelin-1 Transgenic Mice Develop Glomerulosclerosis, Interstitial Fibrosis, and Renal Cysts but not Hypertension" J. Clin. Invest., Vol. 99, No. 6, March 1997, 1380-1389.	
	9.	MILANO, ET AL., "Myocardial expression of a constitutively active •1B-Adrenergic receptor in transgenic mice induces cardiac hypertrophy" Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 10109-10113, October 1994,	
	10.	ZUSCIK, ET AL., "Overexpression of the •1B-adrenergic receptor causes apoptotic neurodegeneration: Multiple system atrophy" Nature Medicine, Vol. 6, No. 12, December 2000, pp. 1388-1394.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

Sheet

1

of

2

**Complete if Known**

<b>Application Number</b>	<b>10/052,589</b>
---------------------------	-------------------

<b>Filing Date</b>	<b>January 18, 2002</b>
--------------------	-------------------------

First Named Inventor	Dianne M. Perez
----------------------	-----------------

Group Art Unit	1632
----------------	------

Examiner Name	Not yet assigned
---------------	------------------

Attorney Docket Number	26473/04200
------------------------	-------------

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+